TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18978388

Group type: EXPERIMENTAL
Intervention: Dental amalgam for posterior restorations
Number of subjects: 66

Group type: COMPARATOR
Intervention: Resin-based composite restorations
Number of subjects: 66
Study: 15979735

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg i.v. dexamethasone preoperatively
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12838354

Group type: EXPERIMENTAL
Intervention: Telephone reminders from General Practitioners (GP)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Telephone reminders from Hospitals
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no telephone reminders)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combined telephone-reminded group (GP + Hospital)
Number of subjects: 109
Study: 10954376

Group type: EXPERIMENTAL
Intervention: Bidirectional filters (BF) applied to 340 patients
Number of subjects: 598

Group type: COMPARATOR
Intervention: Spectral filters (SF) applied to 258 patients
Number of subjects: 598
Study: 8727868

Group type: EXPERIMENTAL
Intervention: Felodipine (Plendil) 10 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2050168

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 6841933

Group type: EXPERIMENTAL
Intervention: Part-time employment (20 hours per week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no part-time employment)
Number of subjects: 55
Study: 30760311

Group type: EXPERIMENTAL
Intervention: Patient-maintained propofol sedation (PMPS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Anaesthetist-controlled propofol sedation (ACPS)
Number of subjects: 2
Study: 28418835

Group type: EXPERIMENTAL
Intervention: DT2 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMP4 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abstinent Contingent Housing (ACH3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Base Case
Number of subjects: 0
Study: 25377788

Group type: EXPERIMENTAL
Intervention: Percentage dose protocol (group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fixed dose protocol (group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 24370761

Group type: EXPERIMENTAL
Intervention: Reference transport modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rolling cart transport modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backpack transport modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shoulder strap transport modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-overweight group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 0
Study: 22186814

Group type: EXPERIMENTAL
Intervention: Single-visit endodontic therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multiple-visit endodontic therapy
Number of subjects: 32
Study: 20051190

Group type: EXPERIMENTAL
Intervention: Educational intervention (questionnaire and additional explanation)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (verbal and written instructions)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Dietary instructions (liquid vs solid food consumed)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Time since last solid meal
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Elapsed time to first bowel movement from initiation of bowel preparation
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Age younger than 55
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Adequate bowel preparation
Number of subjects: 164
Study: 17725757

Group type: EXPERIMENTAL
Intervention: Cryoablation of accessory pathways
Number of subjects: 39
Study: 15199366

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 11383595

Group type: EXPERIMENTAL
Intervention: Infliximab (5, 10, or 20 mg/kg body weight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11
Study: 9923056

Group type: EXPERIMENTAL
Intervention: Intranasal levocabastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8055605

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both bupivacaine groups
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 0.25% bupivacaine
Number of subjects: 39
Study: 2787155

Group type: EXPERIMENTAL
Intervention: Transtympanal electrical stimulation at the promontory
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Masking by hearing aids or tinnitus maskers
Number of subjects: 462
Study: 4456575

Group type: EXPERIMENTAL
Intervention: Coumarin prophylaxis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 14

Group type: COMPARATOR
Intervention: Small doses of heparin
Number of subjects: 14
Study: 31005374

Group type: EXPERIMENTAL
Intervention: GPCATGA+/TMA+AG patients
Number of subjects: 304
Study: 28202475

Group type: EXPERIMENTAL
Intervention: Carbohydrate (50 g) added to standard white-bread challenge
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Protein (50 g) added to standard white-bread challenge
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fat (11.1 g) added to standard white-bread challenge
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fiber (4.8 or 9.6 g) added to standard white-bread challenge
Number of subjects: 22
Study: 26415035

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (1 mg/kg/day) for six months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23850467

Group type: EXPERIMENTAL
Intervention: Attended tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unattended tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congruent tones
Number of subjects: 0
Study: 21547406

Group type: EXPERIMENTAL
Intervention: Sonic frequency diastolic vibro‐percussion (50 Hz, 2 mm amplitude) applied upon the rib‐spaces of the left sternal border
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Third Inter-Costal Space (ICS) proximate the left sternal border
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fourth Inter-Costal Space (ICS) proximate the left sternal border
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Third Inter-Costal Space (ICS) right sternal border
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fourth Inter-Costal Space (ICS) right sternal border
Number of subjects: 90
Study: 17426747

Group type: EXPERIMENTAL
Intervention: Various staple carbohydrate-rich foods (33 foods including breads, breakfast cereals, pasta, rice, and potatoes)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Glucose (25 or 50 g portions)
Number of subjects: 42
Study: 16402242

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rabeprazole (40 mg)
Number of subjects: 18
Study: 12926337

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open surgery (OG)
Number of subjects: 200
Study: 10715293

Group type: EXPERIMENTAL
Intervention: Sucralfate (1.5 g orally every 6 hours)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 123
Study: 9363870

Group type: EXPERIMENTAL
Intervention: RT-PCR dot-blot analysis for CEA mRNA
Number of subjects: 24
Study: 1586618

Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, doxorubicin 50 mg/m2, prednisone 50 mg/m2)
Number of subjects: 89

Group type: COMPARATOR
Intervention: CNOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, mitoxantrone 10 mg/m2, prednisone 50 mg/m2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 89

Group type: COMPARATOR
Intervention: CNOP
Number of subjects: 89
Study: 3839679

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31704907

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI (n=92)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI for 19DEL mutant NSCLC
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI for L858 mutant NSCLC
Number of subjects: 153

Group type: COMPARATOR
Intervention: Single EGFR-TKI (n=61)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI
Number of subjects: 153
Study: 29310138

Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity program
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1635
Study: 27154810

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for two weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal diet for two weeks
Number of subjects: 46
Study: 24669010

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radical cystectomy alone (RC)
Number of subjects: 130
Study: 22986565

Group type: EXPERIMENTAL
Intervention: Single-session walk-in counselling services
Number of subjects: 0
Study: 19573727

Group type: EXPERIMENTAL
Intervention: Rescue percutaneous coronary intervention (R-PCI)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Repeat thrombolysis
Number of subjects: 427

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: R-PCI
Number of subjects: 427
Study: 17288699

Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER) 1000 mg once daily for 5 days
Number of subjects: 818

Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days or telithromycin 800 mg once daily for 5 days (comparator)
Number of subjects: 818
Study: 16091224

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized choice of initial ART regimen
Number of subjects: 0
Study: 12494803

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (n = 22), 10 mg/h during 2 h then 5 mg every 4 h
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nebulized adrenaline (n = 22), 6 mg/h during 2 h then 3 mg every 4 h
Number of subjects: 44
Study: 9829018

Group type: EXPERIMENTAL
Intervention: Abecarnil
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451

Group type: COMPARATOR
Intervention: Active controls
Number of subjects: 451
Study: 7795005

Group type: EXPERIMENTAL
Intervention: Assertive Case Management (ACM) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital program patients
Number of subjects: 0
Study: 2920500

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine infusion (0.44 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 1082383

Group type: EXPERIMENTAL
Intervention: TNM1 vaccine
Number of subjects: 21063

Group type: COMPARATOR
Intervention: Tetanus toxoid (Control)
Number of subjects: 21063
Study: 31957691

Group type: EXPERIMENTAL
Intervention: Real‐RNI training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham‐RNI training
Number of subjects: 0
Study: 30958062

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (300 mg of caffeine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28028822

Group type: EXPERIMENTAL
Intervention: Transobturator tension-free vaginal tapes (TO-TVT)
Number of subjects: 48
Study: 25545858

Group type: EXPERIMENTAL
Intervention: Varenicline (dose increased to a maximum of 5 mg/d)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 503
Study: 24005782

Group type: EXPERIMENTAL
Intervention: Standard care supported by input from remote experts
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 39
Study: 21806795

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage (LL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hartmann's Procedure (HP)
Number of subjects: 80
Study: 19099294

Group type: COMPARATOR
Intervention: Cannabis cigarettes containing 0 mg THC (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 29.3 mg THC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 49.1 mg THC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 69.4 mg THC
Number of subjects: 24
Study: 16469601

Group type: EXPERIMENTAL
Intervention: Tolterodine (2 mg twice daily)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 15223887

Group type: EXPERIMENTAL
Intervention: Topical analgesic
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11295378

Group type: EXPERIMENTAL
Intervention: Training on the Wisconsin Card Sort Test (WCST‐T)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Training on the Halstead Category Test (CAT‐T)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No training (No‐T)
Number of subjects: 33
Study: 9234921

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cisplatin, vincristine, and bleomycin every 3 weeks for four courses)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 122
Study: 8215728

Group type: EXPERIMENTAL
Intervention: Nortriptyline (50 to 150 mg/mL for 6 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 3631199

Group type: EXPERIMENTAL
Intervention: Automated accommodative facility training
Number of subjects: 5
Study: 29289540

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d (n=67)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Glargine at a starting dose of 0.1 U/kg/d (n=73)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d
Number of subjects: 140

Group type: COMPARATOR
Intervention: Glargine at a starting dose of 0.1 U/kg/d
Number of subjects: 140
Study: 27474257

Group type: EXPERIMENTAL
Intervention: 10 mg of the proton pump inhibitor (rabeprazole)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24743122

Group type: COMPARATOR
Intervention: Standard procedure (Antibiotics, systemic metronidazole, antihistamines, traditional external therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rutin Forte (2 capsules per day)
Number of subjects: 30
Study: 22023376

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake, insulin boluses, and bouts of exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor and activity monitor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10-min plasma glucose measurements and plasma insulin and glucagon analyses
Number of subjects: 12
Study: 20123226

Group type: EXPERIMENTAL
Intervention: rt‐PA treatment between 0401 and 0800 hours
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: rt‐PA treatment between 0000 and 0400 hours
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo treatment with stroke onset between 1801 and 2400 hours
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Stroke onset between 0001 and 0400 hours
Number of subjects: 624
Study: 18845005

Group type: EXPERIMENTAL
Intervention: 29G/5-bevel needle with TPE shield
Number of subjects: 5

Group type: COMPARATOR
Intervention: 27G/3-bevel needle with standard rubber shield
Number of subjects: 5
Study: 15833777

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.1, 2.1, 2.9, 4.3, 7.1 microg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.7, 1.4, 4.3, 8.6 microg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0, 100, 300, 1000, 3000 microg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl (0, 50, 68, 90 microg kg(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12970212

Group type: EXPERIMENTAL
Intervention: Low-dose target range (INR 1.8 to 2.8 for aortic position and 2.5 to 3.5 for mitral position)
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Conventional target range (INR 2.5 to 4.5 for all valve positions)
Number of subjects: 3318

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3318
Study: 10372723

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg x h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 9050631

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 20
Study: 1769820

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 149
Study: 6763943

Group type: EXPERIMENTAL
Intervention: Diazepam (Valium)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 31831073

Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program (13-module training delivered via webinar over 3 months in weekly 60-90 minute sessions)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 180
Study: 29074542

Group type: EXPERIMENTAL
Intervention: Inhaled RV568 (50 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled RV568 (100 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled RV568
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26333723

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Ang‐2 levels above the median at day 1
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Stratification of patients according to Ang‐2 levels at day 3
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Ang‐2 concentrations
Number of subjects: 189
Study: 23720399

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n = 22)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-adherence subgroup (from exercise group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-adherence subgroup (from exercise group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention control group (n = 20)
Number of subjects: 42
Study: 22642800

Group type: EXPERIMENTAL
Intervention: Test absorbent pad
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual absorbent pad
Number of subjects: 60
Study: 18561007

Group type: EXPERIMENTAL
Intervention: Self-Administered Interview (SAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free recall
Number of subjects: 0
Study: 17451803

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 100/6 microg bid as maintenance and reliever
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Budesonide 400 microg bid and terbutaline as reliever
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Budesonide/formoterol 100/6 microg bid and terbutaline as reliever
Number of subjects: 2760
Study: 15832861

Group type: EXPERIMENTAL
Intervention: Face Former therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional myofunctional therapy (Control)
Number of subjects: 45
Study: 15896747

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1,500 mg twice a day
Number of subjects: 650

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1.5 to 3 mg/kg in 4 daily doses
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 650
Study: 10593427

Group type: EXPERIMENTAL
Intervention: ioxaglate 320 (dimeric, ionic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iomeprol 400 (monomeric, nonionic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iobitridol 350 (monomeric, nonionic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iodixanol 320 (dimeric, nonionic)
Number of subjects: 60
Study: 8726758

Group type: EXPERIMENTAL
Intervention: NaP solution
Number of subjects: 97

Group type: COMPARATOR
Intervention: PEG-ELS
Number of subjects: 97
Study: 1819801

Group type: EXPERIMENTAL
Intervention: Rubber cup polishing with flour of pumice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prophy‐Jet airpolishing device
Number of subjects: 30
Study: 6758252

Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin and pyrazinamide (regimen 1)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin (regimen 2)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (regimen 4)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimen of isoniazid, rifampicin, and ethambutol (regimen 3)
Number of subjects: 833
Study: 31094782

Group type: EXPERIMENTAL
Intervention: Buccal oxygen administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham oxygenation
Number of subjects: 20